Newsletter

Disclaimer

View this email in your browser

Good afternoon members,

 Update Can-Fite Biopharma (NYSE-MKT: CANF)

 Again? Twice in a row? Yup! Our new alert CANF was by far the #1 gainer in the entire AMEX exchange until about 3-3:15 PM when it became obvious that after we hit the 75% gains mark at $4.30/share, profit taking dominated the remainder of the trading session. Congrats to those who obviously pulled profits along the way.

 In our original report below we mentioned Roth Capital had issued a $15 price target last year. That was actually upgraded based on clinical results afterward to a $28 target. 

 News out today from (CANF) 
 11-18-14 Can-Fite Near-Term Milestones Timetable for 2014/2015
 http://www.prnewswire.com/news-releases/can-fite-near-term-milestones-timetable-for-20142015-283029641.html

 Matter of fact CANF has been on our radar for a while due to the fact we keep a close watch on these FDA trials and the FDA approval/trial calendar’s. Scroll down to the date 03/31/2015 at the following link: http:// http://www.biopharmcatalyst.com/fda-calendar/

 Day one of our coverage CANF opened at $2.51/share and hit a mid-day high, moving slow and steady of $4.30/share for over 70% gains. 

 CANF was trading at $6.75/share on January 15th, 2014. As the story progresses, FDA approvals and positive results will obviously leave a lot of future catalyst opportunities for those of you that like and hold this one long term. 

 We are looking at Monday around market open for our next alert due to the short holiday week coming.

 The Team

 Our original report below issued 11-18-14 9:30 AM Eastern

 The Oracles of Small-Caps are back with yet another potential triple digit gainer this week. 

 Tiny float, bottomed over sold chart, at/near 52 week lows and on the verge of biotech breakthrough. This one could move fast this week with such a low share structure and perfect chart setup.

 Can-Fite Biopharma (NYSE-MKT: CANF) 

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and just completed successful Phase II trials for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 Phase II trial will start enrolling patients shortly. CF102 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and is approved for Compassionate Use by Israel’s Ministry of Health. The Company’s drug candidates have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. The Company’s intellectual property portfolio consists of 150 patents issued and pending.

 (NYSE-MKT: CANF) Highlights

 Nothing but the facts: http://smallcapir.com/wp-content/uploads/2014/11/2014-11-04-CANF-FactSheet_FINAL1.pdf

 Power Point Presentation: http://smallcapir.com/wp-content/uploads/2014/11/11-7-2014-Can-Fite-Presentation-BR_FINAL0001-1.pdf

 Older Analysis by Roth Capital with $15 price target, prior to the up list to the NYSE: http://smallcapir.com/wp-content/uploads/2014/11/ROTH-Capital-Analysis-1.pdf

 This should get everyone in our group familiar with Can-Fite Biopharma for now.

 As always we will have more on this week’s feature alert (NYSE-MKT: CANF) as well as an updated analyst report soon.

 The Team

 Disclaimer

 By agreeing to this disclaimer it indicates you have read and understand the full disclaimer. You will receive the full research report and additional profiles, alerts and updates from Small Cap Specialists, LLC newsletters.  All information provided on any websites owned or managed by Small Cap Specialists, LLC and/or our newsletter and/or any distributed publication and/or media delivered through and/or by Small Cap Specialists, LLC pertaining to investing, stocks, securities must be understood as information provided and not investment advice.  None of the information provided in this website constitutes a recommendation that any investment is suitable for any person.  We advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in any stock including those featured on any of Small Cap Specialists, LLC ’s (herein referred to as the “Group”) websites, publications, applications, software, or other branded media including but not limited to the websites owned or managed by Small Cap Specialists, LLC (herein referred to as “SCS Websites”).

 No Tolerance SPAM Policy: We will not sell or re-distribute your Email to any 3rd party. If applicable, please unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails.

 Small Cap Specialists, LLC  HAS NEVER and WILL NEVER accept free trading shares on behalf of ANY companies listed on SCS Websites or in our email newsletter, or other Social Media.

 We encourage all to read the SEC’s INVESTOR ALERT before reading our Newsletter.

 http://www.sec.gov/oiea/investor-alerts-bulletins/ia_newsletters.html#.U58yGvldXzI

 All information provided regarding the companies featured on SCS Websites is provided in public forums directly from the companies themselves and contained within the Issuers’ SEC filings, OTC Disclosure & News Service filings, news releases, company websites as well as other sources of publicly available information. The profiles of Issuers’ does not represent a solicitation or recommendation to buy, sell, or hold these or any other securities. The receiver of SCS Websites shall not create, under any circumstances, any implication that there has been no change in the affairs of the issuers’ profiled since the date of the review.  The advertisements within SCS Websites are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

 Past performance may not be indicative of future results. Therefore, you should not assume that the future performance of any specific investment or investment strategy will be profitable or equal to corresponding past performance levels. Each investment decision you make should be determined with reference to the specific information available for such investment, and not based upon the success of past recommendations.

 This website and information within the website contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in an any featured equities’ regulatory filings and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. Any forward-looking statements found on SCS Websites are made as of the date thereof and the Group undertakes no obligation to update such statements.

 An investment in an OTC security is speculative and involves a high degree of risk. Many OTC securities are relatively illiquid, or “thinly traded,” which tends to increase price volatility. Illiquid securities are often difficult for investors to buy or sell without dramatically affecting the quoted price. In some cases, the liquidation of a position in an OTC security may not be possible within a reasonable period of time.

 The Group (and our Media Publications/Products) is periodically compensated for describing certain securities of the issuers highlighted on SCS Websites. StocksImpossible's parent company has been compensated up to thirty thousand dollars by Pride Media LLC for investor relations services of CANF. In addition, in some instances the Group and SCS Websites’s affiliates, officers, directors and employees may also have bought or may buy, or have sold or may sell the securities discussed in SCS Websites and may profit in the event of a rise in value of those securities. If the Group owners, management or family members have a position in any securities highlighted on SCS Websites it will be listed in the disclaimer. Each investor must make that decision based on his or her circumstances and judgment of market conditions under the counsel of a licensed Financial Advisor, Broker,  or Dealer.

 The Group does not review, and is not responsible for confirming, the accuracy of documents pertaining to issuers that are publicly traded and information submitted to the Group for inclusion in SCS Websites. The issuers and their management are solely responsible for the accuracy of any information regarding their security that has been provided to the Group for dissemination in SCS Websites. INVESTORS ARE URGED TO CONFIRM THE ACCURACY OF ANY INFORMATION OBTAINED FROM SCS WEBSITES PRIOR TO MAKING ANY INVESTMENT DECISION.

 The Group volunteers disclosure of company compensation pertaining to public companies’ securities. We DO NOT engage in private transactions which may involve; Restricted Securities, Convertible Liabilities, Options Contracts, Warrants, Subscriptions, Exception Specific Securities, Corporate Bonds, and other financial instruments.

 Small Cap Specialists, LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission, FINRA, and is not a Broker/Dealer. The group does not engage in high frequency trading.

 Our mailing address is:

Small Cap Specialists LLC

105 N Michigan Ave, Chicago, IL
Chicago, IL 60601

Add us to your address book

 unsubscribe from this list    update subscription preferences 

Stocks covered:	Compensation:	Avg $ Volume for Period:
CANF	$30000	UNKNOWN
Max Profit: 71.31 %	Gain at close: 19.52 %
*We think that this promoter is a part of a group of promoters.

Newsletter

The oracles do it again #1 gainer in the market Nov 18, 2014 17:20